Aflibercept
(Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1) 目录号 : GC68628Aflibercept 是一种高亲和力的可溶性诱饵血管内皮生长因子受体（Vascular Endothelial Growth Factor, VEGF）和强效血管生成抑制剂，能以极高的亲和力结合血管内皮生长因子和胎盘生长因子 (PlGF)。临床前研究表明，Aflibercept 对黑色素瘤和实体瘤等多种肿瘤具有强大的抗肿瘤和抗血管生成活性。
Cas No.:862111-32-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >97.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
Cell lines | Human RPE (hTERT-RPE1) cells |
Preparation Method | Human RPE (hTERT-RPE1) cells were treated with Aflibercept (7.5μg/ml) for 10min. |
Reaction Conditions | Aflibercept: 7.5μg/ml; 10min |
Applications | Aflibercept (7.5μg/ml; 10min) inhibits galectin-1-mediated VEGFR2 activation. |
| Animal experiment [2]: | |
Animal models | Orthotopic murine renal cancer cell model |
Preparation Method | Aflibercept 10 and 25mg/kg versus solvents control was administered subcutaneously twice-weekly for up to 30 days. |
Dosage form | 10 and 25mg/kg; SC; twice-weekly; 30d |
Applications | Aflibercept (10 and 25mg/kg; SC; twice-weekly; 30d) inhibited primary tumor growth by 74% and 78% and Formation of detectable lung metastases was inhibited in 98% of cases. |
References: | |
Aflibercept is a high-affinity soluble decoy vascular endothelial growth factor (VEGF) receptor and a potent angiogenesis inhibitor that binds vascular endothelial growth factor and placental growth factor (PlGF) with extremely high affinity. Preclinical studies have shown that Aflibercept has potent antitumor and antiangiogenic activities against a variety of tumors, including melanoma and solid tumors[1].
Aflibercept (7.5μg/ml; 10min) inhibits galectin-1-mediated VEGFR2 activation[2]. Aflibercept (15nM; 1h) does not exhibit significant cell surface binding to ARPE-19 and HUVEC. Aflibercept (500nM; 10-15min) in the presence of heparin was unable to stimulate serotonin release[3].
Aflibercept (10 and 25mg/kg; SC; twice-weekly; 30 days) inhibited primary tumor growth by 74% and 78% and Formation of detectable lung metastases was inhibited in 98% of cases [4] . Aflibercept (10mg/kg; 3h) can reduce stroke-induced VEGF-A and VEGFR2 expression, alleviate brain edema and Blood-Brain Barrier disruption, and improve the survival rate of obese mice after stroke after middle cerebral artery occlusion (MCAO) [5].
References:
[1] Bender J G, Blaney S M, Borinstein S, et al. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report[J]. Clinical cancer research, 2012, 18(18): 5081-5089.
[2] Kanda A, Noda K, Saito W, Ishida S. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep. 2015 Dec 9;5:17946.
[3] MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis. 2016 Jul;19(3):389-406.
[4] Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun;5(5):591-600.
[5] Kim ID, Cave JW, Cho S. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52(8):2637-2648.
Aflibercept 是一种高亲和力的可溶性诱饵血管内皮生长因子受体（Vascular Endothelial Growth Factor, VEGF）和强效血管生成抑制剂，能以极高的亲和力结合血管内皮生长因子和胎盘生长因子 (PlGF)。临床前研究表明，Aflibercept 对黑色素瘤和实体瘤等多种肿瘤具有强大的抗肿瘤和抗血管生成活性[1]。
Aflibercept（7.5μg/ml；10min）可抑制半乳糖凝集素-1 介导的 VEGFR2 激活[2]。Aflibercept（15nM；1h）与 ARPE-19 和 HUVEC 细胞表面无明显结合。肝素存在下的Aflibercept（500nM；10-15min）无法刺激血清素释放[3]。
Aflibercept（10，25mg/kg；SC；twice-weekly；30d）分别抑制了 74% 和 78%的原发性肿瘤生长，并且在 98% 的病例中抑制了可检测的肺转移形成[4]。Aflibercept（10mg/kg；3h）在大脑中动脉闭塞（MCAO）后可降低中风引起的 VEGF-A 和 VEGFR2 表达，减轻脑水肿和血脑屏障通透性破坏，提高肥胖小鼠中风后生存率[5]。
| Cas No. | 862111-32-8 | SDF | Download SDF |
| 别名 | VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1 | ||
| 分子式 | 分子量 | ||
| 溶解度 | 储存条件 | Sealed and stored at ≤ -30℃ | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。